肺炎桿菌性マウス実験肺炎を場とするCefazolinによる化学療法の解析

書誌事項

タイトル別名
  • EXPERIMENTAL ANALYSIS OF CEFAZOLIN THERAPY OF MURINE PNEUMONIA DUE TO <I>KLEBSIELLA PNEUMONIAE</I>
  • ハイエン カンキンセイ マウス ジッケン ハイエン オ バ ト スル Cefa

この論文をさがす

抄録

The therapeutic effects of cefazolin on the murine pneumonia due to Klebsiella pneumoniae have een studied, utilizing the method for quantitating both intrapulmonary viable bacteria and drug mcentrations.<BR>Klebsiella pneumoniae B-54 inhaled and deposited in the lungs of mice diminished during about 6 ours (initial clearance), and then grew rapidly, making pneumonia throughout the lungs, and killed of the mice within 72 hours.(LD50: 9.7×10 C. F. U./lung). Cefazolin therapy was started 12 ours after infection. M. I. C. of cefazolin against this bacteria is 1.56 μg/ml. Single injection of 50-800 mg/kg of cefazolin was not a curative dose. After s. c. injection of 50 mg/kg, the drug levels murine lungs maintained more than 2 M. I. C. s during 1 hour, however, the bacteria in the lungs tarted to grow at 1 hour after injection, excee ding the number of bacteria before injection 2 to 3 ours after injection.<BR>Then repeated s. c. injeetions of 50 mg/kg of cefazolin were examined. Neither injections q. 12 h. or q. 6 h. were curative. Injections q. 3 h. suppressed the bacterial growth in the lungs, but pneu-Ionia did not cured. Injections both q. 2 h. more than 69 times and q. 1 h. 10 times saved all the lice from pneumonia. The number of viable bacteria in lungs did not decrease gradually, but shored a stationary phase despite of continuous chemotherapy.<BR>The significance of experimental pneumonia, as compared with the reports by WOOD et al.(1941-956), in relation to chemotherapy utilizing the bactericidal antibiotic, cefazolin, was discussed.<BR>On the basis of these results, it may be concluded that administration of antibiotics shoud be started s early as possible, and that a dose and the administration frequency of those antibiotics should be ncreased as high as possible considering side effects.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ